Insider · CIK 0001872280
Kristian Humer
Files at FDMT (4D Molecular Therapeutics, Inc.), FHTX (Foghorn Therapeutics Inc.), FTH (Faeth Therapeutics, Inc.). First filing -, latest -.
In brief
Kristian Humer files SEC Form 4 as CFO and director at FDMT (4D Molecular Therapeutics, Inc.), and also at FHTX (Foghorn Therapeutics Inc.), FTH (Faeth Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Kristian Humer has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 12, 2023 | VRDN Viridian Therapeutics, Inc.\DE | 252,600 0.48% of outstanding | $4.3M | Dec 12, 2023 | $471k |
| Dec 7, 2023 | VRDN Viridian Therapeutics, Inc.\DE | 24,900 0.05% of outstanding | $471k | Dec 7, 2023 | none |
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 9, 2025 | FDMT 4D Molecular Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +480,000 | $0.00 | $0 | 480,000 | Dec 11, 2025 |
| May 21, 2025 | FTH Faeth Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +19,000 | $0.00 | $0 | 19,000 | May 23, 2025 |
| Jan 22, 2025 | FHTX Foghorn Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +120,000 | $4.37 | $524k | 120,000 | Jan 24, 2025 |
Questions about Kristian Humer
Answered from the filings on this page, as of the latest one.
Is Kristian Humer buying or selling?
Kristian Humer has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Kristian Humer's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Kristian Humer has 0.
Where does Kristian Humer file Form 4?
Kristian Humer has filed Form 4 at FDMT (4D Molecular Therapeutics, Inc.) as Chief Financial Officer; FHTX (Foghorn Therapeutics Inc.) as Chief Financial Officer; FTH (Faeth Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.